市场调查报告书
商品编码
1442598
全球人工水晶体市场评估:按类型、材料、应用、最终用户、地区、机会、预测(2017-2031)Intraocular Lens Market Assessment, By Type, By Material, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球人工水晶体市场规模预计将从 2023 年的 50.8 亿美元成长到 2031 年的 77.9 亿美元,预测期内复合年增长率为 5.5%。
白内障盛行率的不断上升已成为许多国家的重大经济和健康挑战,各国政府已启动旨在消除白内障的计画。 白内障是世界上第一大失明原因,许多患者生活在发展中国家。 白内障以及老花眼和上睑下垂等角膜疾病的治疗预计将成为一项社会经济挑战,特别是在获得适当治疗的机会有限的低收入国家。 儘管白内障手术很有效,但对于世界上很大一部分人口来说,它仍然遥不可及,特别是在经济手段和外科医生机会有限的发展中国家。 结果,大量白内障病例仍未治疗,加重了白内障疾病的负担。 对眼睛健康以及新技术的好处和功能的认识是推动市场的主要因素之一。
根据世界卫生组织 (WHO) 2023 年的报告,全球约有 22 亿人患有近视或远视,估计有 9,400 万人患有白内障。马苏。 政府支持的增加和优惠的报销政策正在鼓励更多的患者接受白内障手术,并且越来越多地采用白内障手术设备。 此外,主要国家减少白内障手术积压和提高眼部保健意识的努力预计将推动白内障手术设备市场的成长。
白内障手术数量增加
白内障手术是全球最常见的眼科手术之一,吸引了大量投资和源源不绝的新产品、服务和创新。 随着不断的进步和需求的不断增加,白内障手术的未来充满希望。 到2030年,白内障手术的年均数量预计将增加,患者的平均年龄也预计将上升。 对白内障手术不断增长的需求也蔓延到发展中国家,那里有许多人患有白内障。 2022 年 1 月发表在《科学报告》上的一项研究表明,白内障和眼睑下垂是老年人常见的眼睛问题。 中老年人眼睑下垂盛行率超过10%,白内障影响15%的人口。
单焦点人工水晶体的成本效益推动市场主导
在人工水晶体市场中,廉价的单焦点水晶体市场占有率最大,约占市场的 55%。 这项优势归功于更好的产品报销以及政府加强利用单焦点镜片进行白内障手术。
北美主导人工水晶体市场
北美预计将在全球人工水晶体市场中占据很大份额。 这是由于与视力相关的疾病日益普及、美国和加拿大新技术和产品的高采用率以及对更好的医疗设施的需求迅速增加。 预计该地区将成为白内障手术器械的最大市场,其中美国占最大份额。 根据 2022 年 5 月眼科管理更新,美国有 1.28 亿老花眼患者,随着千禧世代到了 40 岁并出现老花眼,这一数字还在继续增加。 预计这一趋势将在未来几年推动人工水晶体市场的发展。 此外,白内障(包括年龄相关性白内障和先天性白内障)盛行率的增加也预计将促进市场成长。
本报告调查了全球人工水晶体市场,提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素。我们编制分析、案例研究、竞争格局、主要公司简介等等。
Global intraocular lens market is projected to witness a CAGR of 5.5% during the forecast period 2024-2031, growing from USD 5.08 billion in 2023 to USD 7.79 billion in 2031. An intraocular lens (IOL) implant is a synthetic lens placed inside the eye to replace the focusing power of the natural lens, typically as part of cataract surgery. It has been approved as safe and effective by the U.S. Food and Drug Administration since 1981. IOLs are a popular option for improving vision without heavy reliance on contact lenses and glasses.
The increasing prevalence of cataracts presents a significant economic and healthcare challenge in many countries, prompting various governments to initiate programs aimed at eliminating cataracts. Cataracts are the leading cause of blindness worldwide, with most of those affected residing in developing countries. The management of cataracts and even other corneal disorders, such as presbyopia and blepharoptosis, is expected to become a socioeconomic challenge, particularly in low-income nations with limited access to appropriate treatment. Despite the effectiveness of cataract surgery, it remains inaccessible to a large portion of the global population, especially in developing countries where financial means and access to surgeons are limited. As a result, a substantial number of cataract cases remain untreated, contributing to the burden of the disease. This shortcoming is a big reason behind the forthcoming surge in market growth of IOLs. Awareness about eye health and the benefits and features of new technology is one of the primary factors driving the market.
According to a 2023 report by the World Health Organization (WHO), approximately 2.2 billion people globally have near or distant vision impairment, and an estimated 94.0 million people suffer from cataracts. The increasing government support and favorable reimbursement policies have encouraged more patients to undergo cataract surgery, leading to a rise in the adoption of cataract surgery devices. Additionally, initiatives to reduce the backlog of cataract surgeries and the growing awareness of eye care in key countries are expected to drive the market growth for cataract surgery devices.
Increasing Volume of Cataract Surgeries
Cataract surgery is one of the most performed ophthalmic procedures globally. The increasing prevalence of cataracts and associated visual impairments has led to a rise in the number of cataract surgeries performed worldwide. Cataract surgery has the highest volume procedure for the ophthalmic industry, attracting significant investments and a continuous flow of new products, services, and innovations. With continuous advancements and growing demand, the future of cataract surgery is promising. It is projected that by 2030, the average annual volume of cataract surgeries will increase, and the mean age of patients will also increase. The rising demand for cataract surgery is also prevalent in developing countries, where many individuals are affected by cataracts. Various initiatives and organizations are dedicated to addressing the global burden of cataract blindness and increasing access to cataract surgery in developing nations. A study published in Scientific Reports in January 2022 revealed that cataracts and blepharoptosis are prevalent ophthalmic issues among older adults. The prevalence of blepharoptosis in middle-aged to older adults exceeds 10%, while cataracts affect 15% of the population.
Cost Effectiveness of Monofocal IOL is Driving its Dominance in the Market
The intraocular lens market is categorized into monofocal and premium segments. The monofocal segment, which is cheaper, held the largest share of the global intraocular lens market, accounting for around 55% of the market. This dominance is attributed to the products being more favorably reimbursed and the rising number of government initiatives for utilizing monofocal lenses for cataract surgeries. The premium segment, on the other hand, is expected to witness growth prospects, with multifocal IOLs being the most adopted product due to their advantages in treating complex vision problems such as presbyopia or astigmatism. According to an article published in 2023 by the National Institutes of Health (NIH), monofocal lenses are among the most implanted products in the intraocular lens market. The popularity of these products among the general population is due to their favorable reimbursement and has contributed to their growth prospects.
Government Initiatives Acting as Catalyst
The increasing prevalence of cataracts presents a significant economic and healthcare challenge in many countries, prompting various governments to initiate programs aimed at eliminating cataracts. The rise in standalone eye clinics in developed and developing regions is also expected to contribute to the segment's growth. The academic and research institutes segment is expected to attain growth prospects due to active government efforts to train ophthalmologists and the increasing number of doctors opting for fellowship programs to learn about the latest medical technologies. According to a news article published by the Hindu in May 2022, the Government of India proposed a special drive to clear the backlog of cataract surgeries. 7.5 million cataract surgeries were performed in FY2022-FY2023, 9 million cataract surgeries were performed in FY2023-FY2024, and the plan for FY2024-FY2025 is 10.5 million surgeries. The number of cataract surgeries will be done under a special campaign to clear the backlog, and all the Indian states will be given guidance to conduct these procedures.
High Demand for Hydrophobic Acrylic IOLs
Hydrophobic acrylic materials are the leading choice in the IOL industry, holding the largest market share. They are versatile and can be used to manufacture various IOL designs, including monofocal, multifocal, and toric lenses, thereby meeting diverse patient needs. Compared to other IOL materials like silicone, they offer a more cost-effective option while maintaining high quality. Additionally, being water-resistant, they do not readily absorb water, which helps prevent the build-up of protein deposits on the IOL's surface and the associated clouding and vision problems over time. Its high refractive index, low water content, and the ability to be inserted through small incisions make it more widely used in cataract surgeries. The PMMA segment is expected to hold the second-largest market position in the forecast period, particularly in Europe and other regions, due to its cost advantage over acrylic products.
In 2023, Alcon developed a new intraocular lens made from a hydrophobic acrylic named "Clareon PanOptix IOL". Clareon IOL is made from a hydrophobic acrylic with increased water content compared to AcrySof. As per a study conducted in Australia to test the efficacy of the product, majority of eyes that had the Clareon IOL implanted showed Grade 0 glistening (problems that can occur when a patient is undergoing cataract surgery), and 92.9% of the patients had either no posterior capsular opacification (PCO) or PCO that was clinically undetectable. Over the course of the three-year study period, the visual outcomes were excellent and stable.
North America Dominates IOL Market
North America is anticipated to hold a significant share of the global intraocular lens market. This can be attributed to the increasing prevalence of vision-related disorders, high adoption of new technologies and products in the United States and Canada, and a surge in demand for better healthcare facilities. The region is expected to be the largest market for cataract surgery devices, with the United States accounting for a significant share of the market. According to the ophthalmology management's update from May 2022, the United States is home to 128 million presbyopes, a number that continues to grow as millennials reach the age of 40 and develop presbyopia. This trend is expected to drive the intraocular lens market in the coming years. Furthermore, the increasing prevalence of cataract issues, including age-related and congenital cataracts, is projected to contribute to market growth. In 2022, approximately 12 million individuals aged 40 and above in the United States were found to have vision impairment, while 1.2 million Canadians were living with vision loss. These factors are anticipated to fuel the development of the intraocular lens market due to the growing prevalence of eye illnesses and the rising demand for intraocular lenses.
Future Market Scenario (2024 - 2031F)
The future market scenario of the global intraocular lens market is marked by continuous advancements and innovations. Technological advancements are expected to redefine the landscape, by improving the efficacy of cataract surgeries and refractive procedures. The integration of smart technologies, such as adjustable focus lenses and auto-adjusting IOLs, may become more prevalent, offering patients personalized vision correction options. Nanotechnology is expected to play an important role in the development of next-generation IOL materials, promoting improved biocompatibility and optical performance. In January 2022, Aston University announced its partnership with Rayner Intraocular Lenses, the first company in the world to manufacture intraocular lenses (IOLs), to develop the next generation of lenses that give patients a full range of vision without the need for glasses.
Key Players Landscape and Outlook
The global intraocular lens market is characterized by a consolidated structure, with a few major players holding a significant proportion of the market. Alcon Inc. accounts for the highest market share with a strong portfolio, including the ACRYSOF product line, and an established geographical presence. The company has also focused on launching new products and strategic initiatives to increase its market share. Johnson & Johnson Vision Care, Inc. is the second leading player, with a strong market presence in key regions and robust distribution networks. The prominent companies in the intraocular lens market are pursuing acquisitions to strengthen their market presence.
Additionally, they are forming partnerships with non-profit organizations to raise awareness about cataracts and other eye conditions. Furthermore, manufacturers are actively engaged in introducing new products to maintain a robust product portfolio. In January 2023, Bausch + Lomb completed the acquisition of AcuFocus, a privately held company known for its small aperture non-toric extended depth of focus (EDOF) intraocular lens (IOL). This acquisition has provided Bausch + Lomb with access to AcuFocus's innovative IOL technology, including the IC-8 Apthera lens, which received FDA approval in July 2022. Johnson & Johnson Vision Care Inc., announced in December 2022 that the TECNIS Synergy Toric II OptiBlue PC-IOL is now available in India for patients with astigmatism.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.